“For sotatercept, given the significant clinical data we have and the understanding that there are many patients that have already been identified who can benefit for sotatercept on top of the treatments they have, we are expecting a strong launch.”

In context

“will guide how the ACIP makes their decision. Peter Dannenbaum: Great. Anything else? Okay, next question please, Ivy? Operator: Next, we will go to the line of Evan Seigerman from BMO Capital Markets. Please go ahead. Evan Seigerman: Hi, guys. Thank you so much for taking my questions. I was wondering if you could expand on some of the nuances of your guidance. Specifically, do you include meaningful revenues from sotatercept or V116? I’m assuming they are for approval at some point this year. Caroline Litchfield: Thank you for the question, Evan. This is Caroline. As we’ve guided for 2024, we’re very confident in the underlying momentum in our business across Oncology, across Vaccines, across Animal Health. We also are very excited about the potential launches for sotatercept and V116. For sotatercept, given the significant clinical data we have and the understanding that there are many patients that have already been identified who can benefit for sotatercept on top of the treatments they have, we are expecting a strong launch. For V116, as Dean just outlined, we will wait for the FDA approval, the ACIP recommendation. We will then expect MMWR to publish, and therefore, expect to have impact with V116 coming towards the end of this year. Peter Dannenbaum: Great. Thanks, Evan. Next question please, Ivy? Operator: Next, we will go to the line of Terence Flynn from Morgan Stanley. Please go ahead. Terence Flynn: Great. Thanks so much for taking the question. A competitor recently reported some disappointing data with their TROP2 ADC and later line lung. I recognize these TROP2s are all different given the technology, the linkers. But does this impact at all your development strategy for your TROP2 in lung or perhaps increase the need for a biomarker strategy here? Thank you. Dean Li: Yes. This is Dean. Thanks for t”